Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 21, 2013

View Archived Issues

New copper-based diagnostic imaging agents for Alzheimer's disease synthesized

Trovagene enters into pharmaceutical collaboration for oncogene mutation detection study

New collaboration to identify biomarkers of Limb-girdle muscular dystrophy 2B

Pharmacokinetics of propofol prodrugs HX-0969w and fospropofol compared

Inhibition of CDK9 explored for CLL at the University of South Australia

Chinese researchers report synthesis of novel DPP IV inhibitors for type 2 diabetes

Multikinase inhibitor DCB-R0237 shows promise in vivo

Novel LSD1 inhibitors display good pharmacological properties

Discovery Labs submits IND for Aerosurf

NNZ-2566 obtains FDA fast track status for fragile X syndrome

Once-daily Striverdi Respimat approved in first E.U. countries

AbbVie details activity of antibody-drug conjugate ABT-414

Health Canada approves Stivarga for gastrointestinal stromal tumors

MGN-1404 trial starts in malignant melanoma

Bayer Intellectual Property patents new NCX1 inhibitors

Piramal Enterprises synthesizes new anticancer agents

Germany's G-BA confirms benefits of Jetrea in vitreomacular traction

Polish researchers design novel CYP1B1 inhibitors for cancer

German researchers disclose novel mGlu5 receptor antagonists

FDA approves Opsumit for PAH

Array BioPharma and Genentech patent new BACE1 inhibitors

FDA approves Cimzia for ankylosing spondylitis, issues complete response letter for axSpA

Meda completes acquisition of Acton Pharmaceuticals

FDA awards orphan drug marketing exclusivity to Ixiaro for pediatric indication

Gene therapy product for spinal muscular atrophy gets fast track designation from FDA

Ariad discontinues EPIC trial of Iclusig in newly diagnosed CML

FDA issues complete response letter for Iluvien

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...